Market Eyes LiveDENTSPLY SIRONA Inc. (XRAY) Stock Rating & Analysis
MELANY's data-driven read on DENTSPLY SIRONA Inc. · Dental Equipment & Supplies.
Dentsply Sirona is among the world's largest makers of dental equipment and supplies, formed in a 2016 merger of equals between Dentsply International (dental consumables and lab products) and Sirona Dental Systems (advanced dental equipment). Its broad portfolio spans dental consumables, lab products, CAD/CAM and imaging technology, medical devices, and specialty products in orthodontics, endodontics, and implantation. It distributes two-thirds of its dental consumables, technology, and equipment through third-party distributors.
Why XRAY scores 58/100
MELANY scores DENTSPLY SIRONA Inc. 58/100 by weighing eight factors. Here is how XRAY breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
- PEG ratio 0.75 (< 1 = undervalued)
- FCF yield 6.0%
Margins, returns on capital, and balance-sheet strength.
- Gross margin 50%
Direction and relative strength of the recent share-price trend.
History of beating or missing estimates, and where estimates are heading.
What Wall Street price targets and revisions are signalling.
- Institutional net buying +12.4%
Near-term events that could move the stock.
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
Key risks for XRAY
- Short interest 17% of float, high volatility risk on news
- No positive trailing earnings, valuation cannot be anchored to current P/E
Sector and theme context
DENTSPLY SIRONA Inc. sits in the Healthcare sector theme, which MELANY currently rates 39/100 for strength. Theme strength feeds XRAY's momentum and catalyst factors above.
XRAY trade plan (members only)
MELANY has a full position plan for DENTSPLY SIRONA Inc.: a smart entry zone, an alert level, position sizing, and quarterly review triggers. It unlocks free when you create an account.
How MELANY rates XRAY
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. DENTSPLY SIRONA Inc.'s 58/100 reflects speculative factor weighting for its profile. Position framework managed by score-based check-ins, not a fixed holding period.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about XRAY
Is DENTSPLY SIRONA Inc. (XRAY) a buy?
As of 2026-08-10, MELANY rated DENTSPLY SIRONA Inc. Promising with a composite score of 58/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is DENTSPLY SIRONA Inc.'s MELANY score?
DENTSPLY SIRONA Inc. (XRAY) has a MELANY composite score of 58/100, combining valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile, and macro fit.
How is the XRAY stock rating calculated?
MELANY scores XRAY from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
Should I buy DENTSPLY SIRONA Inc. stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates DENTSPLY SIRONA Inc. (XRAY) Promising with a composite of 58/100 as of 2026-08-10. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the XRAY stock price forecast?
MELANY does not publish price targets or forecasts for XRAY. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 58/100 across eight factors for DENTSPLY SIRONA Inc., and re-scores automatically as new price, earnings, and fundamental data arrive.
Is XRAY stock overvalued or undervalued?
MELANY's valuation factor currently reads 89/100 for DENTSPLY SIRONA Inc., where a higher score means the price looks more attractive against earnings, growth, and peers. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives XRAY's read.
What price should I buy XRAY at?
Rather than chasing the current price, MELANY computes a smart entry zone for XRAY: the price area where risk and reward actually favor a new position, plus an alert level and position sizing. The exact levels unlock free when you create a Market Eyes Live account.
What are the risks of buying XRAY stock?
The top risks MELANY currently flags for DENTSPLY SIRONA Inc.: Short interest 17% of float, high volatility risk on news; No positive trailing earnings, valuation cannot be anchored to current P/E. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is DENTSPLY SIRONA Inc. a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 37/100 for DENTSPLY SIRONA Inc., and earnings track record, at 60/100. The 58/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will XRAY stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 51/100 for XRAY right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this XRAY rating?
The rating on this page is a snapshot of MELANY's read as of 2026-08-10. The price shown updates live, but the score is not recomputed on this page. MELANY re-scores XRAY continuously as new price, earnings, and fundamental data arrive, and that current rating is free in the app.
XRAY's entry zone, live alerts, and full trade plan are free either way. The app is our flagship.